

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

- Article Title: Efficacy for Psychopathology and Body Weight and Safety of Topiramate Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials
- Authors: Christoph U. Correll, MD^a; Lawrence Maayan, MD; John Kane, MD; Marc De Hert, MD, PhD; and Dan Cohen, MD, PhD
- **DOI Number:** 10.4088/JCP.15r10373

List of Supplementary Material for the article

- 1. <u>eFigure 1</u> Standardized Mean Difference in Positive and Negative Syndrome Scale (PANSS) or Brief Psychiatric Rating Scale (BPRS) Total Score (Change or Endpoint) By Clozapine vs. Non-Clozapine Antipsychotic Treatment
- 2. <u>eFigure 2</u> Weighted Mean Difference in Body Weight (Change or Endpoint) By Clozapine vs. Non-Clozapine Antipsychotic Treatment

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

© Copyright 2016 Physicians Postgraduate Press, Inc.

It is illegal to post this copyrighted PDF on any website. • © 2016 Copyright Physicians Postgraduate Press, Inc.

Supplementary eFigure 1. Standardized Mean Difference in Positive and Negative Syndrome Scale

(PANSS) or Brief Psychiatric Rating Scale (BPRS) Total Score (Change or Endpoint) By Clozapine vs.

Non-Clozapine Antipsychotic Treatment



Supplementary eFigure 2. Weighted Mean Difference in Body Weight (Change or Endpoint) By

Clozapine vs. Non-Clozapine Antipsychotic Treatment

Study or Subgroup	TOPIRAMATE			Control			Mean Difference		Mean Difference	
	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	I IV, Random, 95% CI	
14.1.1 Augmentation	of Cloza	apine								
Afshar 2009	63.2	20.4	16	68.89	21.2	16	2.4%	-5.69 [-20.11, 8.73]		
Muscatello 2010	-1	12.28	19	0.28	8.57	24	7.7%	-1.28 [-7.78, 5.22]		
Tiihonen 2005	-0.6	3.54	13	-0.56	2.31	13	15.2%	-0.04 [-2.34, 2.26]	-+-	
Subtotal (95% CI)			48			53	25.4%	-0.30 [-2.44, 1.84]	•	
Heterogeneity: Tau ² =	0.00; Ch	ni ² = 0.6	7, df =	2 (P = 0).71); F	² = 0%				
Test for overall effect:	Z = 0.27	(P = 0.	78)							
14.1.2 Augmentation	of Non-	Clozap	ine An	tipsych	otics					
Chengappa 2007	-1.49	3.85	32	2.72	6.44	14	12.6%	-4.21 [-7.84, -0.58]	20 	
Kim 2006	2.66	1.79	30	4.02	2.52	30	17.1%	-1.36 [-2.47, -0.25]	-	
Ko 2005 (100mg)	-1.68	5.3	16	-0.3	2.59	10	13.8%	-1.38 [-4.43, 1.67]		
Ko 2005 (200mg)	-5.35	4.35	17	-0.3	2.59	10	14.6%	-5.05 [-7.67, -2.43]		
Narula 2010	-1.27	2.28	33	6.03	3.99	34	16.5%	-7.30 [-8.85, -5.75]	-	
Subtotal (95% CI)			128			98	74.6%	-3.88 [-6.81, -0.95]	•	
Heterogeneity: Tau ² =	9.58; Ch	ni² = 40.	77, df =	= 4 (P <	0.000	01); l² =	= 90%			
Test for overall effect:	Z = 2.60	(P = 0.	009)							
Total (95% CI)			176			151	100.0%	-3.14 [-5.55, -0.73]	•	
Heterogeneity: Tau ² =	8.56; Ch	ni² = 48.	62, df =	= 7 (P <	0.000	01); l² =	86%			
Test for overall effect:	Z = 2.55	(P = 0.	01)			0.000			-20 -10 0 10 2 avours experimental Favours control	
Test for subaroup diffe	erences:	Chi ² = 3	3.74. df	= 1 (P	= 0.05	$ ^2 = 7$	3.3%	-	avours experimental Pavours control	